

Jordan Gauthier

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5157510/publications.pdf>

Version: 2024-02-01

82
papers

2,885
citations

279798

23
h-index

189892

50
g-index

92
all docs

92
docs citations

92
times ranked

4276
citing authors

#	ARTICLE	IF	CITATIONS
1	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	1.4	277
2	Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.	4.6	271
3	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	1.4	230
4	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	1.4	222
5	Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. <i>Bone Marrow Transplantation</i> , 2020, 55, 675-680.	2.4	206
6	Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. <i>Blood</i> , 2017, 129, 2471-2478.	1.4	200
7	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	1.4	127
8	Taming the beast: CRS and ICANS after CAR T-cell therapy for ALL. <i>Bone Marrow Transplantation</i> , 2021, 56, 552-566.	2.4	113
9	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	1.4	111
10	Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. <i>Current Research in Translational Medicine</i> , 2018, 66, 50-52.	1.8	100
11	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1079-1109.	4.9	96
12	Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives. <i>Current Research in Translational Medicine</i> , 2017, 65, 93-102.	1.8	85
13	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. <i>Blood Advances</i> , 2019, 3, 3062-3069.	5.2	74
14	Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy. <i>Blood Advances</i> , 2022, 6, 2055-2068.	5.2	60
15	CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives. <i>Leukemia</i> , 2019, 33, 2767-2778.	7.2	47
16	Comparison of Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T-Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. <i>Blood</i> , 2018, 132, 299-299.	1.4	43
17	Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin's lymphoma undergoing allogeneic haematopoietic cell transplantation—a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2018, 53, 400-409.	2.4	34
18	Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2016, 51, 1184-1190.	2.4	31

#	ARTICLE	IF	CITATIONS
19	Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy. <i>Bone Marrow Transplantation</i> , 2017, 52, 689-696.	2.4	31
20	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1680-1680.	1.4	31
21	Impact of Wilms' tumor 1 expression on outcome of patients undergoing allogeneic stem cell transplantation for AML. <i>Bone Marrow Transplantation</i> , 2017, 52, 539-543.	2.4	30
22	Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC. <i>Blood</i> , 2015, 126, 3979-3979.	1.4	30
23	Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016, 51, 1313-1317.	2.4	28
24	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. <i>Blood</i> , 2022, 139, 3722-3731.	1.4	28
25	Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC. <i>Bone Marrow Transplantation</i> , 2017, 52, 878-882.	2.4	26
26	Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis. <i>Blood Advances</i> , 2022, 6, 486-494.	5.2	25
27	Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. <i>Expert Review of Hematology</i> , 2022, 15, 305-320.	2.2	25
28	Novel M-Component Based Biomarkers in Waldenström's Macroglobulinemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 164-167.	0.4	23
29	Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes. <i>Transplantation</i> , 2015, 99, 1672-1680.	1.0	19
30	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. <i>Bone Marrow Transplantation</i> , 2020, 55, 1525-1532.	2.4	17
31	Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis. <i>Expert Review of Hematology</i> , 2012, 5, 619-629.	2.2	15
32	Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 551-551.	1.4	15
33	Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy. <i>Blood Advances</i> , 2020, 4, 4869-4872.	5.2	12
34	Immature platelet fraction (IPF): A reliable tool to predict peripheral thrombocytopenia. <i>Current Research in Translational Medicine</i> , 2020, 68, 37-42.	1.8	11
35	Current combinatorial CAR T cell strategies with Bruton tyrosine kinase inhibitors and immune checkpoint inhibitors. <i>Bone Marrow Transplantation</i> , 2021, 56, 2630-2636.	2.4	11
36	Safety and Efficacy of Two Anakinra Dose Regimens for Refractory CRS or Icaans after CAR T-Cell Therapy. <i>Blood</i> , 2021, 138, 2816-2816.	1.4	11

#	ARTICLE	IF	CITATIONS
37	Successful treatment with fingolimod of graft-versus-host disease of the central nervous system. <i>Blood Advances</i> , 2018, 2, 10-13.	5.2	10
38	Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 908-917.e2.	4.4	8
39	Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S9-S10.	2.0	7
40	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. <i>Blood</i> , 2021, 138, 3872-3872.	1.4	7
41	Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 38-39.	1.4	7
42	Allogeneic Transplantation and Chimeric Antigen Receptor-Engineered T-Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 957-970.	2.2	6
43	Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1415-1415.	1.4	6
44	High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics. <i>Blood</i> , 2020, 136, 37-38.	1.4	6
45	Alemtuzumab vs anti- α thymocyte globulin in patients transplanted from an unrelated donor after a reduced intensity conditioning. <i>European Journal of Haematology</i> , 2018, 101, 466-474.	2.2	5
46	The concurrent administration of imatinib with extracorporeal photopheresis leads to complete and durable responses in patients with refractory sclerotic type chronic graft-versus-host disease. <i>Current Research in Translational Medicine</i> , 2020, 68, 71-76.	1.8	5
47	CMV and HSV Pneumonia After Immunosuppressive Agents for Treatment of Cytokine Release Syndrome Due to Chimeric Antigen Receptor- α -modified T (CAR-T)-Cell Immunotherapy. <i>Journal of Immunotherapy</i> , 2021, 44, 351-354.	2.4	5
48	Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival after Repeat Infusions of CD19 CAR-T Cells. <i>Blood</i> , 2019, 134, 201-201.	1.4	5
49	Factors associated with duration of response after CD19-specific CAR-T cell therapy for refractory/relapsed B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7567-7567.	1.6	5
50	Scoring System Based on Post-Transplant Complications in Patients after Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: A Study from the SFGM-TC. <i>Current Research in Translational Medicine</i> , 2019, 67, 8-15.	1.8	4
51	Time from autologous to allogeneic hematopoietic stem cell transplantation impacts post-transplant outcomes in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2020, 55, 1172-1174.	2.4	4
52	Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. <i>Blood</i> , 2021, 138, 529-529.	1.4	4
53	Bone marrow graft as a source of allogeneic hematopoietic stem cells in patients undergoing a reduced intensity conditioning regimen. <i>Bone Marrow Transplantation</i> , 2014, 49, 1492-1497.	2.4	3
54	Minimal detectable disease confirmed by flow cytometry and poor outcome after autologous stem cell transplantation in peripheral T-Cell lymphomas. <i>Bone Marrow Transplantation</i> , 2016, 51, 1617-1619.	2.4	3

#	ARTICLE	IF	CITATIONS
55	CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.. Journal of Clinical Oncology, 2021, 39, 7532-7532.	1.6	3
56	Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes. Blood, 2019, 134, 4294-4294.	1.4	3
57	The DNA Methyltransferase Inhibitor Decitabine Induces DNA Damage, Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Blood, 2012, 120, 1833-1833.	1.4	3
58	Bayesian Phase 1/2 trial designs and cellular immunotherapies: a practical primer. Cell & Gene Therapy Insights, 2019, 5, 1483-1494.	0.1	3
59	Chimeric Antigen Receptor T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia. Cancer Journal (Sudbury, Mass), 2021, 27, 98-106.	2.0	2
60	Severe Cytokine Release Syndrome Is Associated with Impaired Hematopoietic Recovery after CD19-Targeted CAR-T Cell Therapy. Blood, 2019, 134, 3229-3229.	1.4	2
61	Hevylite, a Novel M-Component Based Biomarkers of Response to Therapy and Survival in Waldenstrom Macroglobulinemia. Blood, 2011, 118, 2667-2667.	1.4	2
62	Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells.. Journal of Clinical Oncology, 2018, 36, 7005-7005.	1.6	2
63	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. Blood, 2020, 136, 1-2.	1.4	2
64	Multivariate Analyses Indicate That the Cytokine Response to Lymphodepletion May be Better Associated Than Lymphodepletion Intensity with the Efficacy of CD19 CAR-T Cell Immunotherapy for Aggressive B-Cell Non-Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, S179-S180.	2.0	1
65	Repeat Infusions of CD19 CAR-T Cells: Factors Associated with Response, CAR-T Cell In Vivo Expansion, and Progression-Free Survival. Biology of Blood and Marrow Transplantation, 2020, 26, S267-S268.	2.0	1
66	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1681-1681.	1.4	1
67	Impact of Early Post-Transplant Complications on Survival of Patients with Myelodysplastic Syndrome Undergoing Allo-SCT Following Reduced Intensity Conditioning: An SFGM-TC Study. Blood, 2015, 126, 1922-1922.	1.4	1
68	The EOSÂ® System for the Detection of Bone Lesions in Patients with Multiple Myeloma,. Blood, 2011, 118, 3921-3921.	1.4	1
69	Bone Marrow Involvement Detected By Multi-Parameter Flow Cytometry Predicts Poor Outcome after Autologous Stem Cell Transplantation for Peripheral T-Cell Lymphoma. Blood, 2015, 126, 1972-1972.	1.4	1
70	Long-Term Follow-up and Single-Cell Multiomics Characteristics of Infusion Products in Patients with Chronic Lymphocytic Leukemia Treated with CD19 CAR-T Cells. Blood, 2021, 138, 1749-1749.	1.4	1
71	Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy. Blood, 2021, 138, 886-886.	1.4	1
72	Post-CAR-T Cell Therapy (Consolidation and Relapse): Acute Lymphoblastic Leukaemia. , 2022, , 165-168.		1

#	ARTICLE	IF	CITATIONS
73	Long-Term Follow-Up Of Invasive Aspergillosis In Allogeneic Stem Cell Transplantation Recipients and Leukemia Patients: Differences In Risk Factors and Outcomes. Blood, 2013, 122, 4568-4568.	1.4	0
74	Monitoring of Wilms's Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1265-1265.	1.4	0
75	Plasma Citrulline Level As a Biochemical Marker to Predict and Diagnose Graft-Versus-Host Disease. Blood, 2014, 124, 3931-3931.	1.4	0
76	Contribution of IPSS-R Cytogenetics to Predict Outcome after Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study from the French Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). Blood, 2014, 124, 5609-5609.	1.4	0
77	Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC. Blood, 2015, 126, 5444-5444.	1.4	0
78	Reduced-Intensity and Non-Myeloablative Allogeneic Stem Cell Transplantation from Alternative HLA-Mismatched Donors for Hodgkin's Lymphoma: A Study By the SFGM-TC (Francophone Society of) Tj ETQq0 0 Q.rgBT /Overlock 10 T		
79	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. Blood, 2018, 132, 281-281.	1.4	0
80	Recombinant CD19 Glycomutant Accurately and Reproducibly Detects CD19-Directed CAR-T Cells By Flow Cytometry. Blood, 2021, 138, 1724-1724.	1.4	0
81	Safety and Efficacy Comparison of Two Anakinra Dose Regimens for Refractory CRS or Neurotoxicity after CAR T-Cell Therapy. Transplantation and Cellular Therapy, 2022, 28, S185-S186.	1.2	0
82	Predictors of cytopenias after treatment with axicabtagene ciloleucel in patients with large B-cell lymphoma. Leukemia and Lymphoma, 0, , 1-5.	1.3	0